Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Chemomab Therapeutics Ltd. Sponsored ADR (CMMB : NSDQ)
 
 • Company Description   
Chemomab Ltd. is a clinical-stage biotech company. It focuses on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. The company's product pipeline includes CM-101. Chemomab Ltd., formerly known as Anchiano Therapeutics Ltd., is based in TEL-AVIV, Israel.

Number of Employees: 16

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.16 Daily Weekly Monthly
20 Day Moving Average: 177,129 shares
Shares Outstanding: 18.86 (millions)
Market Capitalization: $21.87 (millions)
Beta: 0.43
52 Week High: $2.55
52 Week Low: $0.87
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -4.92% -8.48%
12 Week 3.57% -12.88%
Year To Date -35.91% -39.98%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
KIRYAT ATIDIM BUILDING 7
-
TEL AVIV,L3 6158002
ISR
ph: 972-77-331-0156
fax: -
ir@chemomab.com http://www.chemomab.com
 
 • General Corporate Information   
Officers
Adi Mor - Chief Executive Officer; Chief Scientific Officer
Nissim Darvish - Chairman
Sigal Fattal - Chief Financial Officer
Alan Moses - Director
Claude Nicaise - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 16385C104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/20/25
Share - Related Items
Shares Outstanding: 18.86
Most Recent Split Date: 3.00 (0.06:1)
Beta: 0.43
Market Capitalization: $21.87 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.20 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.60 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/20/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.10
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 50.00%
vs. Previous Quarter: 12.50%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -106.70
12/31/24 - -104.91
ROA
06/30/25 - -
03/31/25 - -82.18
12/31/24 - -79.22
Current Ratio
06/30/25 - -
03/31/25 - 5.33
12/31/24 - 4.98
Quick Ratio
06/30/25 - -
03/31/25 - 5.33
12/31/24 - 4.98
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 0.55
12/31/24 - 0.72
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©